Better Health,
Brighter Future
Projects
We are committed to providing innovative treatments to patients through iPS cell technology.
Academic and Takeda researchers are working together as ONE TEAM on projects for clinical applications of iPS cells in neurological diseases, cancer, and intractable muscle diseases, etc.
We are committed to developing innovative treatments to patients through iPS cell technology.
Cell therapy, organoid and advanced immunology
Development of a novel immunotherapy using iPSC-derived immune cells
Shin Kaneko (PI, CiRA)
Akira Hayashi (Co-PI, Takeda)
Yoshiaki Kassai (Co-PI, Takeda)
A new research platform with human iPSC-derived neural crest cells and its applications for drug discovery and regenerative medicine
Makoto Ikeya (PI, CiRA)
Hirokazu Matsumoto (Co-PI, Takeda)
Miniature liver technology as a platform for research towards pharmaceutical applications
Takanori Takebe (PI, TMDU)
Yasunori Nio（Co-PI, Takeda）
Genetically defined muscular diseases and cardiomyopathy
Intractable Muscular Disease Project
Drug discovery for intractable muscular disease using patient-derived iPSCs
Hidetoshi Sakurai (PI, CiRA)
Naoto Inukai (Co-PI, Takeda)
Genome Editing Therapy for Muscular Dystrophy Project
Development of novel gene therapy for Duchenne muscular dystrophy, by using genome editing and delivery technologies
Akitsu Hotta (PI, CiRA)
Naoto Inukai (Co-PI, Takeda)
Drug discovery for genetic cardiac disease using a novel iPSC-based platform
Yoshinori Yoshida (PI, CiRA)
Kenichi Imahashi (Co-PI, Takeda)
Neurodegenerative and neurodevelopmental diseases
ALS/ASD Drug Discovery Project
ALS/ASD drug discovery and development using patient derived iPSCs
Haruhisa Inoue (PI, CiRA)
Hiroshi Yukitake （Co-PI, Takeda）
Development of therapeutic agents for rare hereditary diseases using iPS cells
Tadashi Suzuki (PI, RIKEN)
Hiroshi Yukitake（Co-PI, Takeda）
Research assets transferred from T-CiRA to Orizuru Therapeutics
iPS cell-derived cardiomyocytes and iPS cell-derived pancreatic islet cells, which were developed as part of the T-CiRA program, have been transferred to Orizuru Therapeutics Inc., a company established in April 2021, as seeds for regenerative medical products.
The iPS cell-derived cells were developed by T-CiRA’s projects led by CiRA Associate Professor Yoshinori Yoshida and CiRA Junior Associate Professor Taro Toyoda, respectively.
Cardiac Cell Therapy Project
Development of an iPSC-derived cardiomyocyte cell therapy for severe heart failure
Yoshinori Yoshida (PI, CiRA)
Pancreatic Beta Cell Therapy Project
Research on Cell Therapy against Type 1 Diabetes
Taro Toyoda (PI, CiRA)
